The activation of mitogen-activated protein kinase (MAPK) is an early event in the progression of melanoma, according to a report in the December 2002 issue of Clinical Cancer Research.
MAPK may thus represent a therapeutic target. Although melanoma is a classic example of tumor progression, the authors explain, the alterations in signal transduction accompanying the transition from the atypical nevus precursor to radial growth melanoma are poorly understood.
תגובות רוצה להצטרף לדיון?
יש להתחבר כדי להגיב.
התחבראין תגובות עדיין. היה הראשון להגיב!